Venus Remedies, an Indian oncology medicine supplier, has gained 506 marketing approvals in 76 countries for essential cancer drugs in the Philippines, Paraguay, Georgia, and Moldova. This marks a significant milestone in the company's mission to provide affordable cancer drugs.

Venus Remedies obtained marketing approval for topotecan in the Philippines, the region's second-largest market, in the ASEAN region. The company strengthened its position as a leading oncology drug exporter by registering products suchas irinotecan in Paraguay, docetaxel in Georgia, and topotecan and irinotecan in Moldova.

Saransh Chaudhary, President, Global Critical Care, Venus Remedies, said -

“This accomplishment is a decisive move towards achieving our goal of emerging as the top oncology medicine supplier from India in the ASEAN region and further expanding the reach of our cancer drugs in South America and Eastern Europe. With these marketing authorizations, we will be able to further extend our operations to new markets and reaffirm our commitment to provide advanced cancer treatment options with improved outcomes for patients.”

Venus Remedies targets $5 billion Philippine pharmaceutical market, expanding operations in Asia-Pacific and Southeast Asia, focusing on oncology products. The company has submitted over 50 marketing authorizations to the Philippine Health Ministry.

In Paraguay, a $431.9 million pharmaceutical market, the marketing authorization for irinotecan is expected to streamline the registration process for Venus Remedies' oncology drugs in other South American countries, utilizing similar regulatory processes.

Venus Remedies gains marketing authorizations for docetaxel in Georgia and topotecan and irinotecan in Moldova, strengthening its presence in Eastern Europe and the Balkan region. The company also obtained its first chemotherapy drug authorization from Bosnia, expanding its presence in the region.

Akshansh Chaudhary, Executive Director at Venus Remedies, emphasized the significance of these marketing approvals, stating -

“These marketing approvals are testimony to our uncompromising quality standards. We will continue to leverage our expertise, regulatory might, and global partnerships to develop advanced therapies that can make a substantial difference in the lives of patients around the world.”

Venus Remedies' oncology wing has experienced significant expansion with marketing approvals for key cancer drugs in the UK, Malaysia, Oman, Iraq, as well as the recent ones in the Philippines, Paraguay, Georgia, and Moldova. This demonstrates the company's strong

commitment to improving global accessibility to affordable and advanced cancer treatments.